TY - JOUR
T1 - The contemporary management of cancers of the sinonasal tract in adults
AU - Thawani, Rajat
AU - Kim, Myung Sun
AU - Arastu, Asad
AU - Feng, Zizhen
AU - West, Malinda T.
AU - Taflin, Nicholas F.
AU - Thein, Kyaw Zin
AU - Li, Ryan
AU - Geltzeiler, Mathew
AU - Lee, Nancy
AU - Fuller, Clifton David
AU - Grandis, Jennifer R.
AU - Floudas, Charalampos S.
AU - Heinrich, Michael C.
AU - Hanna, Ehab
AU - Chandra, Ravi A.
N1 - Funding Information:
Mathew Geltzeiler reports personal fees from Stryker and Intersect ENT outside the submitted work. Nancy Lee reports personal fees from Merck, Merck EMD, Pfizer, Elsie, and Mirati outside the submitted work. Clifton D. Fuller reports institutional grants from the National Institutes of Health (NIH) National Institute of Dental and Craniofacial Research (NIDCR) Academic Industrial Partnership Grant (R01DE028290), an NIH/National Cancer Institute (NCI) Cancer Center Support Grant Pilot Research Program Award from The University of Texas MD Anderson Cancer Center Support Grant for the Radiation Oncology and Cancer Imaging Program (Grant P30CA016672), and a National Science Foundation (NSF)/NCI Smart Connected Health Program Grant (R01CA257814) during the conduct of the study. He also reports grants to his institution from the NCI Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science Program (R01CA214825); the NSF/NIH Joint Initiative on Quantitative Approaches to Biomedical Big Data program (R01CA225190); an NIH National Institute of Biomedical Imaging and Bioengineering Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787); an NIDCR Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions award (R01DE025248); an NCI Parent Research Project Grant (R01CA258827), an NIH NIDCR Exploratory/Developmental Research Program Grant (R21DE031082); a Small Business Innovation Research Grant Program subaward from Oncospace, Inc. (R43CA254559); a subaward from The Human BioMolecular Atlas Program (HuBMAP) Integration, Visualization & Engagement (HIVE) Initiative (OT2OD026675); a Patient‐Centered Outcomes Research Institute (PCS‐1609‐36195) subaward from Princess Margaret Hospital; an NSF Division of Civil, Mechanical, and Manufacturing Innovation grant (NSF 1933369); and an institutional research grant from Elekta AB; speakers' fees from Elekta AB, the American Association for Physicists in Medicine, the University of Alabama–Birmingham, the Radiological Society of North America, and the European Society for Radiation Oncology; honoraria from the American Society for Clinical Oncology and the National Institutes of Health; travel support from the American Association for Physicists in Medicine, the American Society for Radiation Oncology, and the Radiological Society of North America all outside the submitted; he has applied for a patent (US Patent Application No. 16/631,662, based on International Patent Application No. PCT/US2018/042364), and has received in‐kind software/computer support from Elekta AB, all outside the submitted work. Michael C. Heinrich received partial salary support from the following sources: a research grant from the Jonathan David Foundation, a Veterans Affairs Merit Review Grant (I01BX005358), and a grant from the National Cancer Institute (R21CA263400). Michael C. Heinrich reports personal fees from Blueprint Medicines, Deciphera Pharmaceuticals, and Novartis; royalties from Novartis; and grant funding from Blueprint Medicines and Deciphera Pharmaceuticals outside the submitted work. The remaining authors made no disclosures.
Publisher Copyright:
© 2022 The Authors. CA: A Cancer Journal for Clinicians published by Wiley Periodicals LLC on behalf of American Cancer Society.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Sinonasal malignancies make up <5% of all head and neck neoplasms, with an incidence of 0.5–1.0 per 100,000. The outcome of these rare malignancies has been poor, whereas significant progress has been made in the management of other cancers. The objective of the current review was to describe the incidence, causes, presentation, diagnosis, treatment, and recent developments of malignancies of the sinonasal tract. The diagnoses covered in this review included sinonasal undifferentiated carcinoma, sinonasal adenocarcinoma, sinonasal squamous cell carcinoma, and esthesioneuroblastoma, which are exclusive to the sinonasal tract. In addition, the authors covered malignances that are likely to be encountered in the sinonasal tract—primary mucosal melanoma, NUT (nuclear protein of the testis) carcinoma, and extranodal natural killer cell/T-cell lymphoma. For the purpose of keeping this review as concise and focused as possible, sarcomas and malignancies that can be classified as salivary gland neoplasms were excluded.
AB - Sinonasal malignancies make up <5% of all head and neck neoplasms, with an incidence of 0.5–1.0 per 100,000. The outcome of these rare malignancies has been poor, whereas significant progress has been made in the management of other cancers. The objective of the current review was to describe the incidence, causes, presentation, diagnosis, treatment, and recent developments of malignancies of the sinonasal tract. The diagnoses covered in this review included sinonasal undifferentiated carcinoma, sinonasal adenocarcinoma, sinonasal squamous cell carcinoma, and esthesioneuroblastoma, which are exclusive to the sinonasal tract. In addition, the authors covered malignances that are likely to be encountered in the sinonasal tract—primary mucosal melanoma, NUT (nuclear protein of the testis) carcinoma, and extranodal natural killer cell/T-cell lymphoma. For the purpose of keeping this review as concise and focused as possible, sarcomas and malignancies that can be classified as salivary gland neoplasms were excluded.
KW - head and neck neoplasms
KW - paranasal sinus neoplasms
KW - rare diseases
KW - sinonasal carcinoma
UR - http://www.scopus.com/inward/record.url?scp=85135440937&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135440937&partnerID=8YFLogxK
U2 - 10.3322/caac.21752
DO - 10.3322/caac.21752
M3 - Review article
C2 - 35916666
AN - SCOPUS:85135440937
SN - 0007-9235
VL - 73
SP - 72
EP - 112
JO - CA Cancer Journal for Clinicians
JF - CA Cancer Journal for Clinicians
IS - 1
ER -